Zeyu Yao

ORCID: 0009-0004-5349-9041
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Anesthesia and Neurotoxicity Research
  • Anesthesia and Pain Management
  • Neutropenia and Cancer Infections
  • Inflammatory Bowel Disease
  • S100 Proteins and Annexins
  • Microscopic Colitis
  • Intensive Care Unit Cognitive Disorders
  • Herbal Medicine Research Studies
  • Biosimilars and Bioanalytical Methods
  • Antifungal resistance and susceptibility
  • Maternal and Perinatal Health Interventions
  • Pharmacovigilance and Adverse Drug Reactions
  • Natural Compounds in Disease Treatment
  • Drug-Induced Adverse Reactions
  • Immunodeficiency and Autoimmune Disorders

Tongji Hospital
2024-2025

Huazhong University of Science and Technology
2024-2025

Qinghai Red Cross Hospital
2017-2023

Background: Canakinumab, a humanized anti-IL-1β monoclonal antibody, is known for its ability to suppress IL-1β-mediated inflammation. However, continuous monitoring of safety remains essential. Thus, we comprehensively evaluated the signals canakinumab by data mining from FAERS. Methods: We used disproportionate analysis quantify canakinumab-related adverse events (AEs) using four algorithms. Clinical prioritization detected was assessed with semiquantitative score method. Serious and...

10.3390/ph18010114 article EN cc-by Pharmaceuticals 2025-01-16

Tumor necrosis factor α (TNF-α) inhibitors are widely used to treat inflammatory bowel disease (IBD), but systematic risk assessment of infectious toxicity is still lacking. We disproportional analysis calculate infection-related signals for four TNF-α and compared them with seven other therapies. There were 55,379 reports adverse events (AEs) as a 'primary suspect (PS)' therapy. The median time onset AEs was 113 days (interquartile range [IQR] 14-612). present the strongest toxic signal...

10.1080/14740338.2025.2486309 article EN Expert Opinion on Drug Safety 2025-03-29

Echinocandins belong to the fourth generation of antifungals, and there are no systematic studies on their risk in coagulation dysfunction; this study will predict dysfunction echinocandins using US Food Drug Administration Adverse Event Reporting System (FAERS) database. Data from January 2004 March 2024 were obtained FAERS. We examined clinical characteristics events conducted disproportionality analysis by reporting odds ratios (ROR) compare with full There 313 reports related as primary...

10.1186/s12959-024-00641-4 article EN cc-by-nc-nd Thrombosis Journal 2024-08-23

To investigate the relationships of serum visinin-like protein-1 (VILIP-1), neuron-specific enolase (NSE), and adiponectin (ADP) levels with postoperative cognitive dysfunction (POCD) in elderly patients undergoing general anesthesia provide a reference for prevention treatment POCD.In this retrospective, observational study, 162 who underwent were divided into POCD non-POCD groups according to whether occurred 24 hours after surgery. Serum VILIP-1, NSE, ADP measured.Immediately surgery,...

10.1177/03000605231172447 article EN cc-by-nc Journal of International Medical Research 2023-05-01

Objective To evaluate the effect of combined spinal epidural anesthesia with low dose ropivacaine for labor analgesia in highland. Methods One hundred primiparas who were at full term and spontaneous highland assigned randomly two groups(n=50): group(group A) control B). In group A, 0.1% 3 ml given when cervical dilation cm, then patient controlled pump placed epidural. And withdrawn fetus delivered. B, did not accepted any analgesia. BP, HR scores VAS Bromage determined before...

10.3760/cma.j.issn.1673-4378.2018.04.006 article EN Guoji mazuixue yu fusu zazhi 2018-04-15
Coming Soon ...